119 related articles for article (PubMed ID: 35578876)
1. Development and Evaluation of Biotin Functionalized Fullerenes for the Delivery of Irinotecan to Colon Tumors.
Dhiman S; Kaur A; Gupta GL; Sharma M
Curr Drug Deliv; 2023; 20(7):978-991. PubMed ID: 35578876
[TBL] [Abstract][Full Text] [Related]
2. PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor.
Shi J; Zhang H; Wang L; Li L; Wang H; Wang Z; Li Z; Chen C; Hou L; Zhang C; Zhang Z
Biomaterials; 2013 Jan; 34(1):251-61. PubMed ID: 23069706
[TBL] [Abstract][Full Text] [Related]
3. A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy.
Shi J; Liu Y; Wang L; Gao J; Zhang J; Yu X; Ma R; Liu R; Zhang Z
Acta Biomater; 2014 Mar; 10(3):1280-91. PubMed ID: 24211343
[TBL] [Abstract][Full Text] [Related]
4. A tumor-specific cleavable nanosystem of PEG-modified C60@Au hybrid aggregates for radio frequency-controlled release, hyperthermia, photodynamic therapy and X-ray imaging.
Shi J; Chen Z; Wang L; Wang B; Xu L; Hou L; Zhang Z
Acta Biomater; 2016 Jan; 29():282-297. PubMed ID: 26485168
[TBL] [Abstract][Full Text] [Related]
5. Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo.
Wang J; Xie L; Wang T; Wu F; Meng J; Liu J; Xu H
Acta Biomater; 2017 Sep; 59():158-169. PubMed ID: 28511875
[TBL] [Abstract][Full Text] [Related]
6. Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: Preparation, in-vitro and in-vivo evaluations.
Bhaskaran NA; Jitta SR; Salwa ; Cheruku S; Kumar N; Kumar L
Int J Biol Macromol; 2022 Jun; 211():301-315. PubMed ID: 35568152
[TBL] [Abstract][Full Text] [Related]
7. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
Shi J; Wang B; Wang L; Lu T; Fu Y; Zhang H; Zhang Z
J Control Release; 2016 Aug; 235():245-258. PubMed ID: 27276066
[TBL] [Abstract][Full Text] [Related]
8. Effect of C
Halenova T; Raksha N; Vovk T; Savchuk O; Ostapchenko L; Prylutskyy Y; Kyzyma O; Ritter U; Scharff P
Int J Obes (Lond); 2018 Dec; 42(12):1987-1998. PubMed ID: 30401827
[TBL] [Abstract][Full Text] [Related]
9. Characterization and efficacy of C
Fu C; Gong S; Lin L; Bao Y; Li L; Chen Q
Biomed Pharmacother; 2024 May; 176():116828. PubMed ID: 38810406
[TBL] [Abstract][Full Text] [Related]
10. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
11. A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver.
Melancon MP; Yevich S; Avritscher R; Swigost A; Lu L; Tian L; Damasco JA; Dixon K; Cortes AC; Munoz NM; Liang D; Liu D; Tam AL
Drug Deliv; 2021 Dec; 28(1):240-251. PubMed ID: 33501859
[TBL] [Abstract][Full Text] [Related]
12. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.
Liang BJ; Pigula M; Baglo Y; Najafali D; Hasan T; Huang HC
J Nanobiotechnology; 2020 Jan; 18(1):1. PubMed ID: 31898555
[TBL] [Abstract][Full Text] [Related]
13. Effects intracerebral microinjection and intraperitoneal injection of [60]fullerene on brain functions differ in rats.
Yamada T; Jung DY; Sawada R; Matsuoka A; Nakaoka R; Tsuchiya T
J Nanosci Nanotechnol; 2008 Aug; 8(8):3973-80. PubMed ID: 19049160
[TBL] [Abstract][Full Text] [Related]
14. Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles.
Baker GL; Gupta A; Clark ML; Valenzuela BR; Staska LM; Harbo SJ; Pierce JT; Dill JA
Toxicol Sci; 2008 Jan; 101(1):122-31. PubMed ID: 17878152
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography (PET) guided glioblastoma targeting by a fullerene-based nanoplatform with fast renal clearance.
Peng Y; Yang D; Lu W; Hu X; Hong H; Cai T
Acta Biomater; 2017 Oct; 61():193-203. PubMed ID: 28801268
[TBL] [Abstract][Full Text] [Related]
16. Protective role of fullerenol and arginine C
Bityutskii NP; Yakkonen KL; Napolskikh YM; Pampur D; Yuriev GO; Semenov KN; Letenko DG
Plant Physiol Biochem; 2023 Nov; 204():108095. PubMed ID: 37866064
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
18. Fullerene C
Borisenkova AA; Bolshakova OI; Titova AV; Ryabokon IS; Markova MA; Lyutova ZB; Sedov VP; Varfolomeeva EY; Bakhmetyev VV; Arutyunyan AV; Burdakov VS; Sarantseva SV
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791388
[TBL] [Abstract][Full Text] [Related]
19. Application of C60 Fullerene-Doxorubicin Complex for Tumor Cell Treatment In Vitro and In Vivo.
Panchuk RR; Prylutska SV; Chumakl VV; Skorokhyd NR; Lehka LV; Evstigneev MP; Prylutskyy YI; Berger W; Heffeter P; Scharff P; Ritter U; Stoika RS
J Biomed Nanotechnol; 2015 Jul; 11(7):1139-52. PubMed ID: 26307837
[TBL] [Abstract][Full Text] [Related]
20. C
Hurmach Y; Rudyk M; Prylutska S; Hurmach V; Prylutskyy YI; Ritter U; Scharff P; Skivka L
Mol Pharm; 2020 Sep; 17(9):3622-3632. PubMed ID: 32673486
[No Abstract] [Full Text] [Related]
[Next] [New Search]
